Mr. Etienne Grima reports

CARDIOCOMM ANNOUNCES ADOPTION OF QUARTERLY REPORTING EXEMPTION UNDER COORDINATED BLANKET ORDER 51-933

Cardiocomm Solutions Inc. has elected to rely on Coordinated Blanket Order 51-933 (Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers) and move to semi-annual financial reporting.

Coordinated Blanket Order 51-933 allows eligible venture issuers listed on the TSX Venture Exchange to voluntarily move from a quarterly to a semi-annual financial reporting framework. The company's fiscal year ends on Dec. 31. Under the SAR pilot program:

• Interim period: The company will be exempt from filing an interim financial report and related management's discussion and analysis for the first quarter ended March 31, 2026, and the third quarter ending Sept. 30, 2026.
• Continuing reporting: Cardiocomm will continue to file audited annual financial statements (due within 120 days of Dec. 31, 2026) and six-month interim financial reports (due within 60 days of June 30, 2026).

The company confirms it meets the SAR pilot program's eligibility criteria, which include being a venture issuer with annual revenues of less than $10-million as shown on its most recently filed audited annual financial statements, having been a reporting issuer in at least one jurisdiction of Canada for 12 months or more, and having filed all required periodic and timely disclosure documents under applicable Canadian securities legislation.

This news release is being filed pursuant to Coordinated Blanket Order 51-933 (Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers).

About Cardiocomm Solutions Inc.

Cardiocomm is a health care technology company focused on the development of medical software, remote patient monitoring solutions and data management platforms for the collection, analysis and reporting of cardiac and related physiological data. The company's technologies support patients, physicians and health care organizations through clinically relevant, connected digital health solutions. Cardiocomm has earned the ISO 13485 and ISO 27001 certifications, is HIPAA compliant, and holds medical device clearances and sales licences from the United States (Food and Drug Administration) and Canada (Health Canada).

We seek Safe Harbor.